Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer

• Published in: International journal of cancer Vol. 120; no. 6; pp. 1355 - 1363
• Main Authors: Nakahira, Shin, Nakamori, Shoji, Tsujie, Masanori, Takahashi, Yuji, Okami, Jiro, Yoshioka, Shinichi, Yamasaki, Makoto, Marubashi, Shigeru, Takemasa, Ichiro, Miyamoto, Atsushi, Takeda, Yutaka, Nagano, Hiroaki, Dono, Keizo, Umeshita, Koji, Sakon, Masato, Monden, Morito
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 15.03.2007; Wiley-Liss
• Subjects: Animals; Antimetabolites, Antineoplastic - pharmacology; Antimetabolites, Antineoplastic - therapeutic use; Antineoplastic agents; Biological and medical sciences; Cell Line, Tumor; Cell Proliferation - drug effects; Chemotherapy; Deoxycytidine - analogs & derivatives; Deoxycytidine - pharmacology; Deoxycytidine - therapeutic use; drug resistance; Drug Resistance, Neoplasm - genetics; gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Medical sciences; Mice; microarray; pancreatic cancer; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - genetics; Pancreatic Neoplasms - pathology; Pharmacology. Drug treatments; RNA, Antisense - pharmacology; RNA, Messenger - analysis; RNA, Messenger - metabolism; RRM1; Transfection; Tumor Suppressor Proteins - antagonists & inhibitors; Tumor Suppressor Proteins - genetics; Tumors; Up-Regulation; Antineoplastic agent; Gemcitabine; Gene overexpression; Subunit; pancreatic cancer; Cancerology; Pancreas cancer; Genetics; Ribonucleoside-diphosphate reductase; Pyrimidine nucleoside; Pancreatic disease; Human; Treatment resistance; RRM1; Enzyme; Malignant tumor; Chemotherapy; microarray; Treatment; Antimetabolic; Digestive diseases; Pyrimidine derivatives; Fluorine Organic compounds; Oxidoreductases; drug resistance

Pancreatic cancer is the most lethal of all solid tumors partially because of its chemoresistance. Although gemcitabine is widely used as a first selected agent for the treatment of this disease despite low response rate, molecular mechanisms of gemcitabine resistance in pancreatic cancer still rema...